



Summary of 2023 Annual Flu Strain Reactivity Testing

Because every result matters[™]

Catalogue 1010: Acucy™ Influenza A&B Test, CLIA Waived Kit

A panel of eight human influenza viral strains was provided by the FDA Center for Biologics Evaluation and Research (CBER) for evaluating the reactivity of the Acucy[™] Influenza A&B Test. The viral isolates included four influenza A and four influenza B strains. Each sample was serially diluted in 5-fold dilutions from the stock provided and each dilution was assayed in replicates of five. To create samples for testing, mock patient samples were prepared by pipetting 50 µL of each diluted sample onto a swab. Each swab was tested following the procedure stated in the AcucyTM Influenza A&B Test instructions for use. All strains were successfully detected. The minimally reactive concentration was identified as the lowest dilution at which any of the five replicates gave a positive reading. www.sekisuidiagnostics.com

Influenza Virus	Virus Strain Name	Stock Concentration	ve Results at Each	Dilution						
(Type/Subtype)		(EID ₅₀ /mL)	5x	25x	125x	625x	3,125x	15,625x	78,125x	390,625x
	A/Victoria/4897/2022	11085	2x10 ^{7.5}	4x10 ^{6.5}	8x10 ^{5.5}	1.6x10 ^{5.5}	3.2x10 ^{4.5}	6.4x10 ^{3.5}	1.28x10 ^{3.5}	2.56x10 ^{2.5}
Influenza A/		1x10 ^{8.5}	5/5	5/5	3/5	0/5	0/5	not tested	not tested	not tested
H1N1pdm09	1//interia/2570/2010	1x10 ^{8.3}	2x10 ^{7.3}	4x10 ^{6.3}	8x10 ^{5.3}	1.6x10 ^{5.3}	3.2x10 ^{4.3}	6.4x10 ^{3.3}	1.28x10 ^{3.3}	2.56x10 ^{2.3}
	A/Victoria/2570/2019	1x10 ^{8.3}	5/5	5/5	5/5	5/5	0/5	0/5	not tested	not tested
	A/Darwin/9/2021	1x10 ^{8.3}	2 x 10 ^{7.3}	4 x 10 ^{6.3}	8 x 10 ^{5.3}	1.6 x 10 ^{5.3}	3.2 x 10 ^{4.3}	6.4 x 10 ^{3.3}	1.28 x 10 ^{3.3}	2.56 x 10 ^{2.3}
Influenza A/			5/5	5/5	5/5	5/5	0/5	0/5	not tested	not tested
H3N2	A/Georgia/02/2022	1x10 ^{9.5}	2 x 10 ^{8.5}	4 x 10 ^{7.5}	8 x 10 ^{6.5}	1.6 x 10 ^{6.5}	3.2 x 10 ^{5.5}	6.4 x 10 ^{4.5}	1.28 x 10 ^{4.5}	2.56 x 10 ^{3.5}
			5/5	5/5	5/5	2/5	0/5	0/5	not tested	not tested
	B/Austria/1359417/2021	1x10 ^{8.5}	2 x 10 ^{7.5}	4 x 10 ^{6.5}	8 x 10 ^{5.5}	1.6 x 10 ^{5.5}	3.2 x 10 ^{4.5}	6.4 x 10 ^{3.5}	1.28 x 10 ^{3.5}	2.56 x 10 ^{2.5}
Influenza B/			5/5	5/5	1/5	0/5	0/5	not tested	not tested	not tested
Victoria Lineage	B/Netherlands/10894/2022	1x10 ^{8.7}	2 x 10 ^{7.7}	4 x 10 ^{6.7}	8 x 10 ^{5.7}	1.6 x 10 ^{5.7}	3.2 x 10 ^{4.7}	6.4 x 10 ^{3.7}	1.28 x 10 ^{3.7}	2.56 x 10 ^{2.7}
			5/5	5/5	5/5	0/5	0/5	not tested	not tested	not tested
	B/Phuket/3073/2013	1x10 ^{7.8}	2 x 10 ^{6.8}	4 x 10 ^{5.8}	8 x 10 ^{4.8}	1.6 x 10 ^{4.8}	3.2 x 10 ^{3.8}	6.4 x 10 ^{2.8}	1.28 x 10 ^{2.8}	2.56 x 10 ^{1.8}
Influenza B/ Yamagata Lineage			5/5	5/5	5/5	0/5	0/5	not tested	not tested	not tested
		1x10 ^{9.5}	2 x 10 ^{8.5}	4 x 10 ^{7.5}	8 x 10 ^{6.5}	1.6 x 10 ^{6.5}	3.2 x 10 ^{5.5}	6.4 x 10 ^{4.5}	1.28 x 10 ^{4.5}	2.56 x 10 ^{3.5}
	B/Norway/2134/2019		5/5	5/5	5/5	5/5	0/5	0/5	not tested	not tested





Summary of 2021 Annual Flu Strain Reactivity Testing

Because every result matters[™]

Catalogue 1010: Acucy™ Influenza A&B Test, CLIA Waived Kit

A panel of eight human influenza viral strains was provided by the Centers for Disease Control for evaluating the reactivity of the Acucy™ Influenza A&B Test. The viral isolates included four influenza A and four influenza B strains. Each sample was serially diluted in 5-fold dilutions from the stock provided and each dilution was assayed in replicates of five. To create samples for testing, mock patient samples were prepared by pipetting 50 µL of each diluted sample onto a swab. Each swab was tested following the procedure stated in the AcucyTM Influenza A&B Test instructions for use. All strains were successfully detected. The minimally reactive concentration was identified as the lowest dilution at which any of the five replicates gave a positive reading. www.sekisuidiagnostics.com

Influenza Virus	Virus Strain Name	Stock Concentration		Virus 5-Fold Serial Dilutions (EID ₅₀ /mL) and Number of Positive Results at Each Dilution									
(Type/Subtype)		(EID₅₀/mL)	(EID ₅₀ /mL)										
		1x10 ^{8.3}	2x10 ^{7.3}	4x10 ^{6.3}	8x10 ^{5.3}	1.6x10 ^{5.3}	3.2x10 ^{4.3}	6.4x10 ^{3.3}	1.28x10 ^{3.3}	2.56x10 ^{2.3}			
A(112N12)	A/Perth/16/2009	1X1055	5/5	5/5	5/5	5/5	5/5	5/5	0/5	0/5			
A(H3N2)	A /T	11 08 5	2x10 ^{7.5}	4x10 ^{6.5}	8x10 ^{5.5}	1.6x10 ^{5.5}	3.2x10 ^{4.5}	6.4x10 ^{3.5}	1.28x10 ^{3.5}	2.56x10 ^{2.5}			
	A/Tasmania/503/2020	1x10 ^{8.5}	5/5	5/5	5/5	5/5	5/5	0/5	0/5	not tested			
	A/Christ Church/16/2020	1x10 ^{9.2}	2x10 ^{8.2}	4x10 ^{7.2}	8x10 ^{6.2}	1.6x10 ^{6.2}	3.2x10 ^{5.2}	6.4x10 ^{4.2}	1.28x10 ^{4.2}	2.56x10 ^{3.2}			
A(111N11)mdm00			5/5	5/5	5/5	5/5	5/5	0/5	0/5	not tested			
A(H1N1)pdm09	A/Victoria/2570/2019	1x10 ^{8.2}	2x10 ^{7.2}	4x10 ^{6.2}	8x10 ^{5.2}	1.6x10 ^{5.2}	3.2x10 ^{4.2}	6.4x10 ^{3.2}	1.28x10 ^{3.2}	2.56x10 ^{2.2}			
			5/5	5/5	5/5	5/5	5/5	0/5	0/5	not tested			
	B/Michigan/09/2011	1x10 ^{6.9}	2x10 ^{5.9}	4x10 ^{4.9}	8x10 ^{3.9}	1.6x10 ^{3.9}	3.2x10 ^{2.9}	6.4x10 ^{1.9}	1.28x10 ^{1.9}	2.56x10 ^{0.9}			
B (Victoria			5/5	5/5	5/5	5/5	0/5	0/5	not tested	not tested			
lineage)	B/Washington/02/2019	1x10 ^{9.3}	2x10 ^{8.3}	4x10 ^{7.3}	8x10 ^{6.3}	1.6x10 ^{6.3}	3.2x10 ^{5.3}	6.4x10 ^{4.3}	1.28x10 ^{4.3}	2.56x10 ^{3.3}			
		1X1055	5/5	5/5	5/5	5/5	0/5	0/5	not tested	not tested			
	B/Texas/81/2016	1x10 ^{8.1}	2x10 ^{7.1}	4x10 ^{6.1}	8x10 ^{5.1}	1.6x10 ^{5.1}	3.2x10 ^{4.1}	6.4x10 ^{3.1}	1.28x10 ^{3.1}	2.56x10 ^{2.1}			
B (Yamagata			5/5	5/5	5/5	5/5	4/5	0/5	0/5	not tested			
lineage)		1x10 ^{9.9}	2x10 ^{8.9}	4x10 ^{7.9}	8x10 ^{6.9}	1.6x10 ^{6.9}	3.2x10 ^{5.9}	6.4x10 ^{4.9}	1.28x10 ^{4.9}	2.56x10 ^{3.9}			
	B/Phuket/3073/2013		5/5	5/5	5/5	5/5	0/5	0/5	not tested	not tested			



Summary of 2020 Annual Flu Strain Reactivity Testing



Because every result matters[™]

Catalogue 1010: Acucy™ Influenza A&B Test, CLIA Waived Kit

A panel of eight human influenza viral strains was provided by the Centers for Disease Control for evaluating the reactivity of the Acucy[™] Influenza A&B Test. The viral isolates included four influenza A and four influenza B strains. Each sample was serially diluted in 5-fold dilutions from the stock provided and each dilution was assayed in replicates of five. To create samples for testing, mock patient samples were prepared by pipetting 50 µL of each diluted sample onto a swab. Each swab was tested following the procedure stated in the Acucy[™] Influenza A&B Test instructions for use. All strains were successfully detected. The minimally reactive concentration was identified as the lowest dilution at which any of the five replicates gave a positive reading. www.sekisuidiagnostics.com

Influenza Virus	Virus Strain Name	Stock Concentration	Virus 5-Fold Serial Dilutions (EID₅₀/mL) and Number of Positive Results at Each Dilution										
(Type/Subtype)		(EID ₅₀ /mL)											
A(H3N2)	A/Perth/16/2009	1,109.3	2x10 ^{8.3}	4x10 ^{7.3}	8x10 ^{6.3}	1.6x10 ^{6.3}	3.2x10 ^{5.3}	6.4x10 ^{4.3}	1.28x10 ^{4.3}	2.56x10 ^{3.3}	5.12x10 ^{2.3}	1.024x10 ^{2.3}	
		1x10 ^{9.3}	5/5	5/5	5/5	5/5	5/5	0/5	0/5	not tested	not tested	not tested	
	A/Hong	1x10 ^{7.5}	2x10 ^{6.5}	4x10 ^{5.5}	8x10 ^{4.5}	1.6x10 ^{4.5}	3.2x10 ^{3.5}	6.4x10 ^{2.5}	1.28x10 ^{2.5}	2.56x10 ^{1.5}	5.12x10 ^{0.5}	1.024x10 ^{0.5}	
	Kong/2671/2019	1X10 ²¹³	5/5	5/5	0/5	0/5	not tested	not tested	not tested	not tested	not tested	not tested	
A(H1N1)pdm09	A/Christ Church/16/2010	11010.2	2x10 ^{9.2}	4x10 ^{8.2}	8x10 ^{7.2}	1.6x10 ^{7.2}	3.2x10 ^{6.2}	6.4x10 ^{5.2}	1.28x10 ^{5.2}	2.56x10 ^{4.2}	5.12x10 ^{3.2}	1.024x10 ^{3.2}	
		1x10 ^{10.2}	5/5	5/5	5/5	5/5	3/5	0/5	0/5	not tested	not tested	not tested	
	A/Guangdong- Maonan/1536/2019	1x10 ^{9.1}	2x10 ^{8.1}	4x10 ^{7.1}	8x10 ^{6.1}	1.6x10 ^{6.1}	3.2x10 ^{5.1}	6.4x10 ^{4.1}	1.28x10 ^{4.1}	2.56x10 ^{3.1}	5.12x10 ^{2.1}	1.024x10 ^{2.1}	
			5/5	5/5	5/5	0/5	0/5	not tested	not tested	not tested	not tested	not tested	
	B/Michigan/09/2011	1 1x10 ^{6.9}	2x10 ^{5.9}	4x10 ^{4.9}	8x10 ^{3.9}	1.6x10 ^{3.9}	3.2x10 ^{2.9}	6.4x10 ^{1.9}	1.28x10 ^{1.9}	2.56x10 ^{0.9}	4.07	0.813	
B (Victoria			5/5	5/5	5/5	0/5	0/5	not tested	not tested	not tested	not tested	not tested	
lineage)	B/Washington/02/2019	shington/02/2019 1x10 ^{9.2}	2x10 ^{8.2}	4x10 ^{7.2}	8x10 ^{6.2}	1.6x10 ^{6.2}	3.2x10 ^{5.2}	6.4x10 ^{4.2}	1.28x10 ^{4.2}	2.56x10 ^{3.2}	5.12x10 ^{2.2}	1.024x10 ^{2.2}	
		1X105.2	5/5	5/5	5/5	5/5	0/5	0/5	not tested	not tested	not tested	not tested	
B (Yamagata lineage)	B/Texas/81/2016	xas/81/2016 1x10 ^{8.3}	2x10 ^{7.3}	4x10 ^{6.3}	8x10 ^{5.3}	1.6x10 ^{5.3}	3.2x10 ^{4.3}	6.4x10 ^{3.3}	1.28x10 ^{3.3}	2.56x10 ^{2.3}	5.12x10 ^{1.3}	1.024x10 ^{1.3}	
			5/5	5/5	5/5	5/5	1/5	0/5	0/5	not tested	not tested	not tested	
	B/Phuket/3073/2013	3 1x10 ^{9.9}	2x10 ^{8.9}	4x10 ^{7.9}	8x10 ^{6.9}	1.6x10 ^{6.9}	3.2x10 ^{5.9}	6.4x10 ^{4.9}	1.28x10 ^{4.9}	2.56x10 ^{3.9}	5.12x10 ^{2.9}	1.024x10 ^{2.9}	
		1710	5/5	5/5	5/5	4/5	0/5	0/5	not tested	not tested	not tested	not tested	





Summary of 2019 Annual Flu Strain Reactivity Testing

Because every result matters[™]

Catalogue 1010: Acucy™ Influenza A&B Test, CLIA Waived Kit

A panel of eight human influenza viral strains was provided by the Centers for Disease Control for evaluating the reactivity of the Acucy™ Influenza A&B Test. The viral isolates included four influenza A and four influenza B strains. Each sample was serially diluted in 5-fold dilutions from the stock provided and each dilution was assayed in replicates of five. To create samples for testing, mock patient samples were prepared by pipetting 50 µL of each diluted sample onto a swab. Each swab was tested following the procedure stated in the Acucy[™] Influenza A&B Test instructions for use. All strains were successfully detected. The minimally reactive concentration was identified as the lowest dilution at which any of the five replicates gave a positive reading. www.sekisuidiagnostics.com

Influenza Virus	Virus Strain Name	Stock Concentration		Virus 5-Fold Serial Dilutions (EID ₅₀ /mL) and Number of Positive Results at Each Dilution									
(Type/Subtype)		(EID50/mL)											
	A/Perth/16/2009	1x10^8.3	2x10^7.3	4x10^6.3	8x10^5.3	1.6x10^5.3	3.2x10^4.3	6.4x10^3.3	1.28x10^3.3	2.56x10^2.3	5.12x10^1.3	1.024x10^1.3	
			5/5	5/5	5/5	5/5	5/5	1/5	0/5	0/5	not tested	not tested	
A(H3N2)	A /// /1 4 /2017*	11048.0	2x10^7.9	4x10^6.9	8x10^5.9	1.6x10^5.9	3.2x10^4.9	6.4x10^3.9	1.28x10^3.9	2.56x10^2.9	5.12x10^1.9	1.024x10^1.9	
	A/Kansas/14/2017*	1x10^8.9	5/5	5/5	5/5	5/5	5/5	0/5	0/5	0/5	not tested	not tested	
	A/Christ Church/16/2010	1x10^9.9	2x10^8.9	4x10^7.9	8x10^6.9	1.6x10^6.9	3.2x10^5.9	6.4x10^4.9	1.28x10^4.9	2.56x10^3.9	5.12x10^2.9	1.024x10^2.9	
A(H1N1)pdm09			5/5	5/5	5/5	5/5	5/5	4/5	0/5	0/5	not tested	not tested	
	A/Brisbane/02/2018*	1x10^7.9	2x10^6.9	4x10^5.9	8x10^4.9	1.6x10^4.9	3.2x10^3.9	6.4x10^2.9	1.28x10^2.9	2.56x10^1.9	5.12x10^0.9	1.024x10^0.9	
			5/5	5/5	5/5	5/5	5/5	5/5	0/5	0/5	not tested	not tested	
	B/Michigan/09/2011	2011 1x10^8.5	2x10^7.5	4x10^6.5	8x10^5.5	1.6x10^5.5	3.2x10^4.5	6.4x10^3.5	1.28x10^3.5	2.56x10^2.5	5.12x10^1.5	1.024x10^1.5	
B (Victoria			5/5	5/5	5/5	5/5	0/5	0/5	not tested	not tested	not tested	not tested	
lineage)	B/Colorado/06/2017*	11040.2	2x10^7.3	4x10^6.3	8x10^5.3	1.6x10^5.3	3.2x10^4.3	6.4x10^3.3	1.28x10^3.3	2.56x10^2.3	5.12x10^1.3	1.024x10^1.3	
		1x10^8.3	5/5	5/5	5/5	5/5	0/5	0/5	not tested	not tested	not tested	not tested	
B (Yamagata lineage)	B/New	11048.0	2x10^7.9	4x10^6.9	8x10^5.9	1.6x10^5.9	3.2x10^4.9	6.4x10^3.9	1.28x10^3.9	2.56x10^2.9	5.12x10^1.9	1.024x10^1.9	
	Hampshire/01/2016	16 1x10^8.9	5/5	5/5	5/5	5/5	0/5	0/5	not tested	not tested	not tested	not tested	
		[*] 1x10^8.9	2x10^7.9	4x10^6.9	8x10^5.9	1.6x10^5.9	3.2x10^4.9	6.4x10^3.9	1.28x10^3.9	2.56x10^2.9	5.12x10^1.9	1.024x10^1.9	
	B/Phuket/3073/2013*		5/5	5/5	5/5	5/5	0/5	0/5	not tested	not tested	not tested	not tested	

*CDC recommended strains for use in the 2019-2020 influenza season vaccine (northern hemisphere).